Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic ref...
Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9639 6036
Fax: 61 3 9639 6030
Address:
55 Collins Street, Level 38, Melbourne, Australia
